The European Commission’s (EC) deeper scrutiny of conglomerate effects in its review of Bayer‘s [ETR:BAYN] proposed acquisition of Monsanto [NYSE:MON] is adding complexity to the review, sources familiar with the situation indicated.
These could translate to difficulties in remedy design, a source familiar with the matter and a third-party source said. EC officials are plodding through documents in their investigation of the deal, which is at a formal halt pending Bayer and Monsanto’s reply to a request for information (RFI).
Third parties have not received any recent RFIs, according to the first and a second third-party source.
Sign in to view the full article.